Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 5Wilms Tumor 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Hepatoblastoma 1Adrenocortical Carcinoma 1

Interventions

X-Rays 4Phantoms, Imaging 4Cyclophosphamide 4Specimen Handling 3Melphalan 3Magnetic Resonance Spectroscopy 3Granulocyte Colony-Stimulating Factor 3Busulfan 3ulixertinib 2tipifarnib 2tazemetostat 2talazoparib 2selpercatinib 2palbociclib 2ivosidenib 2fludarabine 2cabozantinib 2Vemurafenib 2Topotecan 2Temozolomide 2Sirolimus 2Nuclear Medicine Department, Hospital 2Nivolumab 2LY3023414 2Filgrastim 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1regorafenib 1racotumomab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × cixutumumab × Genitourinary × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡